With a more favourable environment, ONO PHARMACEUTICAL improves to Positive
ONO PHARMACEUTICAL (JP), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date February 25, 2022, the closing price was JPY 2,806.00 and its potential was estimated at JPY 3,087.26.Ono Pharmaceutical is a pharmaceutical company. Co. is engaged in the production, purchase and sale of pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals. Co.'s pharmaceuticals include peripheral circulation improving agents, bronchial asthma and allergic rhinitis medication, pediatric bronchial asthma medications, acute lung injury associated medications and others. Co.'s principal products include Rivastach® Patch, Glactiv® Tablets, Emend® Capsules, Recalbon® Tablets, Staybla® Tablets, Opalmon® Tablets, Onon® Capsules, Onon® Dry Syrup, Kinedak® Tablets and others. In addition, Co. is also engaged in the medical research on lipid metabolism disorder.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.